Risk adjusted net present value: What is the current valuation of Forte Biosciences’s FB-102?

FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Celiac Disease.

Are back problems influenced by your gut?

Findings suggest gut microbiome dysbiosis may influence lumbar degenerative spondylolisthesis, impacting inflammation and pain management strategies.

October 25, 2024

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity – Biotech Investments

Biophytis / Key word(s): Miscellaneous/Miscellaneous Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity 11-Jul-2024 / 08:13 CET/CEST

July 12, 2024

Novel PARP1 Inhibitor Shows Promise in Breast Cancer

SAN DIEGO — Saruparib, an investigational selective PARP1 inhibitor, showed promising activity in patients with certain homologous recombination repair (HRR)-deficient breast cancers, while limiting toxicity,

April 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.